Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 23,334 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 23,334 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10. Following the transaction, the executive vice president directly owned 160,000 shares of the company’s stock, valued at $6,264,000. This trade represents a 12.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Down 1.5%

Shares of NASDAQ:RPRX traded down $0.58 during trading hours on Tuesday, hitting $38.09. The company’s stock had a trading volume of 5,257,951 shares, compared to its average volume of 4,309,095. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The firm’s fifty day moving average price is $37.93 and its 200 day moving average price is $36.44. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $41.24. The company has a market capitalization of $21.99 billion, a price-to-earnings ratio of 28.86, a P/E/G ratio of 2.09 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The company had revenue of $609.29 million for the quarter, compared to the consensus estimate of $765.01 million. As a group, research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, November 14th. Royalty Pharma’s dividend payout ratio is 66.67%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. The Goldman Sachs Group started coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 target price on the stock. Weiss Ratings cut Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Morgan Stanley lowered their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Finally, TD Cowen cut Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.00.

Institutional Trading of Royalty Pharma

Hedge funds have recently modified their holdings of the business. Tudor Investment Corp ET AL raised its holdings in Royalty Pharma by 34.4% during the third quarter. Tudor Investment Corp ET AL now owns 863,835 shares of the biopharmaceutical company’s stock worth $30,476,000 after purchasing an additional 221,099 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Royalty Pharma by 28.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,759,620 shares of the biopharmaceutical company’s stock worth $62,079,000 after acquiring an additional 386,108 shares during the period. CIBC Bancorp USA Inc. acquired a new position in Royalty Pharma in the third quarter valued at $480,000. Alpine Global Management LLC purchased a new position in shares of Royalty Pharma during the 3rd quarter worth about $513,000. Finally, WBI Investments LLC acquired a new position in shares of Royalty Pharma in the 3rd quarter valued at $1,915,000. 54.35% of the stock is owned by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.